GlassScriptPhysician profile
Edgar Cruz
NPI 1578662581
$4,799.64
in general payments reported to CMS, 2019-2025
22 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2021: $530 · 2022: $453 · 2023: $2,325 · 2024: $500 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,819 · Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,819.23 |
| Food and Beverage | $1,719.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,819.23 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,725.50 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $194.26 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $191.54 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $152.07 | 2024-2025 | Mounjaro |
| Amarin Pharma, INC. | $135.03 | 2019 | |
| Boston Scientific Corporation | $87.31 | 2021-2024 | |
| Exact Sciences Corporation | $86.01 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $71.87 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Genentech USA, INC. | $54.35 | 2019 | |
| Glaxosmithkline, LLC. | $42.76 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.33 | 2025 | Jardiance |
| Tolmar, INC. | $30.20 | 2025 | Jatenzo |
| Eisai INC. | $25.91 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.86 | 2023 | Nuedexta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $22.74 | 2023 | Mavenclad |
| Merck Sharp & Dohme LLC | $20.72 | 2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $19.27 | 2025 | |
| Corcept Therapeutics | $19.13 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $16.68 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $16.11 | 2025 | |
| Inspire Medical Systems, INC. | $13.76 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.